Anti-CD3-anti-HER2-activated T cells

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAnti-CD3-anti-HER2-activated T cells
Drug Alias NameHER2Bi-armed ATCAnti-CD3 activated T cells targeted with anti-CD3-anti-HER2 bispecific antibody,ATC targeted with HER2Bi
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBone metastasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTranstarget
China Registration ClassN/A

Develop Information

Active CompaniesBarbara Ann Karmanos Cancer Institute
Inactive CompaniesTranstargetNational Cancer Institute
Active IndicationsBone metastasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A